Abstract
Abstract
Background
Before COVID-19, people with rare diseases (RD) experienced numerous disparities in quality of life and healthcare access and quality, yet little is known about the experiences of this underserved group during the pandemic.
Results
During the first wave of the COVID-19 pandemic in the United States, spring and summer of 2020, 759 participants representing 231 unique RDs responded to open-ended questions about the impact of the pandemic on life with a RD, healthcare access, and coping. Qualitative conventional content analysis was used to analyze responses. Identified themes represented positive and negative dimensions of change, including a shock to the (health) system, coping with uncertainty, and the value of social support while isolated.
Conclusions
Limitations in healthcare access and quality were the most frequently described as impacts of COVID-19. Other major negative impacts included exacerbation of symptoms, psychological distress, and a lack of usual social support and reliable information. However, participants also noted silver linings, especially in healthcare. For some, expanded telehealth enhanced their ability to access medical and mental health providers and RD specialists. Finally, many participants hoped that, by highlighting social and health inequities faced by people with RDs and other minorities, the pandemic would prompt greater understanding and policies that could improve the quality of life of the RD community.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference16 articles.
1. National Institutes of Health, Genetic and Rare Diseases Information Center. FAQs About Rare Diseases [Internet]. [cited 2017 Oct 27]. Available from: https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases
2. Orphanet. About rare diseases [Internet]. [cited 2017 Nov 24]. Available from: http://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN
3. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.
4. Bryson B, Bogart K, Atwood M, Fraser K, Locke T, Pugh K, et al. Navigating the unknown: a content analysis of the unique challenges faced by adults with rare diseases. J Health Psychol. 2019;21:1359105319828150.
5. EURORDIS. Rare diseases: understanding this public health priority [Internet]. 2005 [cited 2017 Jul 9]. Available from: http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf